



- (51) **International Patent Classification:**
A61K 31/4164 (2006.01)
- (21) **International Application Number:**
PCT/US2013/027983
- (22) **International Filing Date:**
27 February 2013 (27.02.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
13/406,321 27 February 2012 (27.02.2012) US
- (71) **Applicant:** EYE THERAPIES, LLC [US/US]; 26933 Camino De Estrella, Dana Point, CA 92624 (US).
- (72) **Inventor:** HORN, Gerald; 1150 Heather Road, Deerfield, IL 60015 (US).
- (74) **Agents:** POLYAKOV, Mark V. et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) **Date of publication of the international search report:**
12 March 2015



WO 2013/130577 A3

(54) **Title:** COMPOSITIONS AND METHODS FOR THE TREATMENT OF MIGRAINE

(57) **Abstract:** Pharmaceutical compositions for the treatment of migraine, wherein the pharmaceutical composition formulated as a nasal spray or as a oral formulation comprises low concentrations of a superselective subclass of alpha-2 adrenergic receptor agonists, that have a binding affinity of 900 fold or greater for alpha-2 over alpha-1 adrenergic receptors, such as, for example, dexmedetomidine.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 13/27983

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A61K 31/4164 (2013.01)
 USPC - 514/396
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC(8): A61K 31/4164 (2013.01)
 USPC: 514/396

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC: 514/816; 424/434 (text search) Find search terms below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PubWEST, Google Scholar, PatBase
 alpha-2 adrenergic, \$adrenergic, agonist, desmedetomidine, nasal, intranasal, composition, formulation, administ\$, oral\$, poloxamer, migraine, pain, treat\$

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2011/0257188 A1 (HORN) 20 October 2011 (20.10.2011) para [0009], [0028]-[0029], [0031], [0061], [0064]-[0065]	1-5 ----- 6 and 9
X -- Y	US 2011/0021588 A1 (HENWOOD et al.) 27 January 2011 (27.01.2011) para [0004]-[0006], [0030], [0042], [0045]	7 and 10 ----- 8-9
Y	US 2002/0192288 A1 (WILLIAMS et al.) 19 December 2002 (19.12.2002) para [0008], [0014], [0030]	6
Y	US 2009/0220611 A1 (DARGELAS et al.) 03 September 2009 (03.09.2009) para [0001], [0048]-[0061], [0186], [0226]	8
A	US 6,486,190 B1 (CUPPS et al.) 26 November 2002 (26.11.2002) col 5, ln 36 - col 6, ln 21	1-10

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:
 "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed
 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search 14 April 2013 (14.04.2013)	Date of mailing of the international search report 13 MAY 2013
---	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--